Announcement • May 29

Apogee Therapeutics Announces Positive 16-Week Part B Induction Dose Optimization Results from Phase 2 Apex Trial of Zumilokibart in Moderate-To-Severe Atopic Dermatitis

Apogee Therapeutics announced positive 16-week data from Part B of the Phase 2 APEX clinical trial of zumilokibart (APG777), a potential best-in-class anti-IL-13 antibody, in patients with moderate-to-severe atopic dermatitis. The trial met its primary and secondary endpoints with high statistical significance including 65.9% of patients treated with mid-dose zumilokibart achieving EASI-75 (41.9% placebo adjusted). Based on these dose optimization results and subject to regulatory interactions, Apogee plans to move forward with the mid-dose, which achieved the best clinical activity of the three doses tested and was well-tolerated, in its Phase 3 trials. The APEX Phase 2 clinical trial is a randomized, placebo-controlled study evaluating zumilokibart in patients with moderate-to-severe atopic dermatitis. In Part B, 346 adult patients were dosed after being randomized 1:1:1:1 to high-, mid- or low-dose zumilokibart versus placebo. The primary endpoint is the proportion of patients who achieve an Eczema Area and Severity Index (EASI) percent score reduction of at least 75 (EASI-75) at Week 16. Secondary endpoints include Validated Investigator's Global Assessment (IGA) 0/1, EASI-90, Itch Numeric Rating Scale (I-NRS 4), EASI-100, and Very Low Disease Activity (vLDA; EASI-90 + I-NRS 0/1) at Week 16. The trial met its primary endpoint, with mid- and high-doses of zumilokibart demonstrating comparable efficacy and both doses outperforming low dose and placebo with EASI-75 scores at Week 16: High dose: 61.6% achieved EASI-75 (p<0.001 vs placebo), Mid dose: 65.9% achieved EASI-75 (p<0.001 vs placebo), Low dose: 50.5% achieved EASI-75 (p<0.001 vs placebo), Placebo: 23.4% achieved EASI-75. Mid-dose zumilokibart met key secondary endpoints at Week 16: IGA 0/1 response in 46.0% of patients, compared to 10.9% in the placebo arm (p<0.001), EASI-90 response in 47.4% of patients, compared to 9.3% in the placebo arm (p<0.001), I-NRS 4 reduction from baseline in 50.5% of patients, compared to 13.9% in placebo arm (p <0.001), EASI-100 response in 16.5% of patients, compared to 3.4% in the placebo arm (p<0.01), vLDA response in 20.6% of patients, compared to 4.5% in the placebo arm (p<0.01). Zumilokibart was well tolerated, with a safety profile generally consistent with other agents in the class. The most common treatment-emergent adverse events (TEAEs) in zumilokibart-treated patients were nasopharyngitis, headache, and noninfective conjunctivitis. For the planned Phase 3 dose (mid dose), the pooled conjunctivitis rate (all conjunctivitis preferred terms) was 10.6%, compared to 15.1% for the low dose and 20.7% for the high dose. Based on results from the APEX clinical program, Apogee plans to initiate Phase 3 trials of zumilokibart for moderate-to-severe atopic dermatitis in the second half of 2026, pending regulatory interactions. Apogee has also disclosed planned trial designs for its asthma and eosinophilic esophagitis (EoE) programs, further supporting zumilokibart's potential as a pipeline-in-a-product opportunity across multiple inflammatory and immunology diseases. The ADventure 1 and ADventure 2 trials are randomized, placebo-controlled, replicate Phase 3 monotherapy trials evaluating zumilokibart in patients with moderate-to-severe atopic dermatitis (EASI 16, vIGA 3, BSA 10%). Each study is expected to enroll approximately 400 patients and includes a 16-week induction period followed by maintenance through Week 52. In maintenance, patients will receive dosing every three or six months. The co-primary endpoint is EASI-75 and IGA 0/1 at Week 16, with additional assessment at Week 52. The ADventure TCS Phase 3 trial will evaluate zumilokibart in combination with background topical corticosteroids in patients with moderate-to-severe atopic dermatitis (EASI 16, vIGA 3, BSA 10%). The randomized, placebo-controlled study is expected to enroll approximately 400 patients and includes a 16-week induction period and maintenance through Week 52. The co-primary endpoint is EASI-75 and IGA 0/1 at Week 16, with longer-term outcomes assessed at Week 52. The ASPIRE Phase 2b trial is a randomized, placebo-controlled study evaluating multiple dosing regimens of zumilokibart in patients with moderate-to-severe asthma with elevated Type 2 biomarkers and a history of exacerbations. The study is designed to be potentially registrational and is expected to enroll approximately 500 patients randomized across dosing intervals of every three, six, or twelve months, or placebo. The primary endpoint is annualized exacerbation rate at Week 52, with additional assessments of lung function and symptoms. The ELEVATE Phase 2a trial is an open-label, proof-of-concept study evaluating zumilokibart in patients with eosinophilic esophagitis. The study is expected to enroll approximately 30 to 50 patients and will assess dosing every three or six months. The primary endpoint is histologic response, including reductions in eosinophil counts, with additional evaluation of endoscopic findings and patient-reported outcomes. The Company described expected program readouts and milestones through 2028. Initiation of Phase 3 ADventure 1 and ADventure 2 monotherapy (16-week) clinical trials expected second half of 2026. Initiation of Phase 3 ADventure TCS combination (16-week) clinical trial expected second half of 2026. Phase 2 APEX Part B (52-week) maintenance data expected first half of 2027. Phase 2 APEX Part A 2-year follow-up data expected second half of 2027. Phase 3 ADventure 1 and ADventure 2 monotherapy (16-week) data readout expected first half of 2028. Phase 3 ADventure TCS combination (16-week) data readout expected second half of 2028. Launch anticipated in 2029. Initiation of Phase 2b ASPIRE trial expected first half of 2027. Initiation of Phase 2a ELEVATE trial expected second half of 2026. Phase 2a ELEVATE data readout expected second half of 2027. Phase 2a ELEVATE long-term follow-up data expected second half of 2028. Phase 1b head-to-head clinical trial of APG279 (IL-13 + OX40L) vs. DUPIXENT for moderate to severe atopic dermatitis data readout expected second half of 2026. Announce further clinical plans for APG273 (zumilokibart+APG333) in second half of 2026. Announce additional pipeline program in first half of 2027. Zumilokibart (APG777) is a novel, subcutaneous extended half-life monoclonal antibody targeting IL-13 - a critical cytokine in inflammation and a primary driver of atopic dermatitis. In the APEX Phase 2 Part A 52-week trial, zumilokibart demonstrated potential to maintain and deepen clinical responses with as little as every 3- and 6-month dosing.

Announcement • Dec 02

Apogee Therapeutics Highlights Progress and Best-In-Class Potential of Novel Biologic Programs for I&I Diseases At 2024 Inaugural R&D Day Include

Apogee Therapeutics, Inc., Updated include positive interim results from the APG808 Phase 1 trial, data up to 12 months from the APG777 Phase 1 trial, details around the Company’s strategy for combinations in AD, asthma and COPD to deliver better efficacy and dosing regimens, and the expected significant commercial potential of its programs. Key opinion leaders, Emma Guttman-Yassky, M.D., Ph.D. and David Singh, M.D., FERS, FBPhS, will also discuss the current landscape and need for new treatment opportunities for patients living with I&I conditions. APG808 interim Phase 1 healthy volunteer trial results; The APG808 Phase 1 trial enrolled 32 healthy adult participants into four single-ascending dose (SAD) cohorts. Today, Apogee shared interim data from all four SAD cohorts with at least 3-months follow-up: APG808 demonstrated a potential best-in-class PK profile, including a half-life of approximately 55 days, supporting the potential for every 2- to 3- month maintenance dosing. Single doses of APG808 demonstrated a deep and sustained effect on pharmacodynamic (PD) markers out to approximately 3 months (longest follow-up available at time of data cut). APG808 was well tolerated across all dose groups. Apogee is also now evaluating APG808 in a Phase 1b trial in patients with asthma, with data expected in the first half of 2025. Accelerating a leading franchise in AD; Apogee is advancing multiple opportunities for best-in-class monotherapy and first-in-class combination approaches for the treatment of AD that could provide transformational dosing and efficacy compared to current approved and investigational biologics. APG777 is a novel, subcutaneous (SQ) extended half-life monoclonal antibody (mAb) targeting IL-13 with the potential for best-in-class efficacy and dosing compared to currently approved biologics. APG777 is being evaluated in an ongoing Phase 1 trial, which initiated in August 2023, and a global Phase 2 trial in AD, which initiated in May 2024. Today, Apogee provided updated data from its Phase 1 trial, which is now out to 12 months, including a half-life of 77 days, consistent safety with prior data and favorable PD profile showing near complete inhibition of pSTAT6 for up to 12 months after a single administration and sustained TARC inhibition. These latest data support the potential path for APG777 to be dosed annually, which could create yet another opportunity to disrupt the future $50B+ AD market that is currently served by therapies that require dosing every 2-4 weeks. The Phase 1 data continue to support Apogee’s ongoing Phase 2 trial of APG777 in patients with AD, demonstrating potential for improved clinical responses from greater exposures in induction and maintenance dosing of every 3- or 6-months. Based on strong enrollment in the Phase 2 trial to date, Apogee now expects to report 16-week topline data from Part A of the APG777 Phase 2 trial in mid-2025. The observed strong correlation between Phase 2 and Phase 3 data makes the 16-week induction data a key catalyst. Apogee plans to advance the development of APG777 in asthma and EoE, by initiating a Phase 1b trial in asthma in the first half of 2025, followed by a Phase 2b trial in asthma in the second half of 2025, and launching a Phase 2 trial in EoE in 2026. Raising the bar in AD and beyond via broader inhibition; Apogee plans to take a first-in-class combination approach to AD by targeting Types 1-3 inflammation potentially offering JAK-like inhibition without their associated safety concerns. This approach offers the potential for improved clinical responses over monotherapies and best-in-class dosing. APG777 + APG99; APG990 is a novel, SQ half-life extended mAb targeting OX40L, initially being developed for AD. OX40L is located further upstream in the inflammatory pathway than IL-13 and targeting it could have broader impact on the inflammatory cascade by inhibiting Type 1, Type 2 and Type 3 pathways. Apogee is evaluating APG990 in a Phase 1 healthy volunteer trial to establish safety, tolerability and PK profile, which would enable combination with APG777. The APG777 + APG990 coformulation has been shown to retain stability, injectability, and convenience of individual components. In preclinical studies it has demonstrated broad inhibition of Type 1, Type 2 and Type 3 inflammation with potential for better tolerability than JAK inhibitors. Pending APG990’s Phase 1 results expected in the first half of 2025, Apogee plans to initiate its first combination trial in 2025 – a Phase 1b trial designed to evaluate the safety, PK, PD and efficacy of the combination of APG777 and APG990 against DUPIXENT in approximately 50-75 patients with moderate-to-severe AD with readout expected in second half of 2026. Breaking through the efficacy ceiling in asthma and COPD; Apogee plans to take a combination approach to the treatment of asthma and COPD, leveraging mechanisms that address both central and local drivers of respiratory diseases, potentially enabling enhanced efficacy and extended dosing regimens. APG777 + APG33; APG333 is a novel, SQ extended half-life mAb targeting TSLP, a key driver of Type 2 and Type 3 inflammation in eosinophilic and non-eosinophilic conditions. A Phase 1 trial in healthy volunteers is planned to commence by the end of 2024, with data expected in the second half of 2025. In preclinical studies, the combination of APG777 + APG333 has been shown to drive broader and deeper inhibition of inflammation centrally with deeper impact on local airway responses compared to approved or in-development biologics, with the potential for a significantly less frequent dosing schedule. Apogee plans to evaluate APG777 and APG333 monotherapies in respective Phase 1b trials in patients with asthma in 2025 to support advancement into future combination trials in asthma and COPD.

Biotechs Industry Growth	17.04%
Revenue growth rate	n/a
Return on equity	-24.64%
Net Margin	n/a
Last Earnings Update	30 Jun 2026

Date	Earnings	G+A Expenses	R&D Expenses
30 Jun 26	-294	83	241
31 Mar 26	-275	76	229
31 Dec 25	-256	71	215
30 Sep 25	-254	67	216
30 Jun 25	-238	63	208
31 Mar 25	-205	56	186
31 Dec 24	-182	49	168
30 Sep 24	-147	42	137
30 Jun 24	-118	36	108
31 Mar 24	-104	30	89
31 Dec 23	-84	25	68
30 Sep 23	-70	19	54
30 Jun 23	-69	12	47
31 Mar 23	-52	7	35

Data	Last Updated (UTC time)
Company Analysis	2026/09/02 20:16
End of Day Share Price	2026/09/02 00:00
Earnings	2026/06/30
Annual Earnings	2025/12/31

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

Analyst	Institution
Tazeen Ahmad	BofA Global Research
Julian Harrison	BTIG
Edward Nash	Canaccord Genuity

This company has been acquired

Apogee Therapeutics Past Earnings Performance

Past criteria checks 0/6

Key information

Recent past performance updates

Recent updates

Apogee Therapeutics, Inc. to Delist Common Stock from Nasdaq

Apogee Therapeutics, Inc.(NasdaqGM:APGE) dropped from Russell 2500 Growth-Dynamic Index

Insufficient new directors

Apogee Therapeutics, Inc. Announces Board and Committee Changes

New minor risk - Share price stability

CEO & Director notifies of intention to sell stock

AbbVie: Why The Pharma Wins Twice With Its Apogee Acquisition

AbbVie Nears $10.9 Billion Cash Deal to Acquire Apogee Therapeutics

Apogee Therapeutics Secures US$1.3b to Advance Zumilokibart for Atopic Dermatitis Trials

Apogee Therapeutics Announces Positive 16-Week Part B Induction Dose Optimization Results from Phase 2 Apex Trial of Zumilokibart in Moderate-To-Severe Atopic Dermatitis

Apogee Therapeutics, Inc. announced that it expects to receive $500 million in funding

High number of new and inexperienced directors

Apogee Therapeutics, Inc., Annual General Meeting, Jun 09, 2026

Apogee Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $350 million.

Apogee Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $300 million.

Apogee Therapeutics, Inc. Announces Positive Phase 2 Part A 52-Week Data Of Zumilokibart (APG777) Demonstrating Maintenance And Deepening Of Responses With Every 3- And 6-Month Dosing In Moderate-To-Severe Atopic Dermatitis

Apogee Therapeutics Announces Positive Interim Results from Phase 1B Trial of Zumilokibart (APG777), Its Potentially Best-In-Class Anti-IL-13 Antibody, in Patients with Mild-To-Moderate Asthma

Apogee Therapeutics Announces Positive Interim Phase 1 Results from Healthy Volunteer Trial of APG333, its Novel Half-Life Extended TSLP Antibody

Apogee Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $300.00003 million.

Apogee Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $300.00003 million.

Apogee Therapeutics, Inc. Announces Late-Breaker Presentation of 16-Week Data from Phase 2 Apex Trial of Apg777 for Moderate-To-Severe At the Upcoming European Academy of Dermatology and Venereology (Eadv) 2025 Congress

Apex, Inc. Announces Positive 16-Week Data from Part A of the Phase 2 Apex Clinical Trial of APG777

Apogee Therapeutics, Inc. Announces Positive Interim Results from the Phase 1B Trial of Apg808, Its Novel Half-Life Extended Il-4Ra Antibody, in Patients with Mild-To-Moderate Asthma

Apogee Therapeutics, Inc., Annual General Meeting, Jun 17, 2025

Apogee Therapeutics: Engineering Biologic Dominance

Apogee Therapeutics, Inc. Announces Positive Interim Phase 1 Results from the APG990 Healthy Volunteer Trial, Unlocking Potential Maintenance Dosing Every Three and Six Months for APG990

Apogee Therapeutics, Inc. Announces First Patient Dosed in Part B of Phase 2 APEX Trial of APG777 in Patients with Moderate-To-Severe Atopic Dermatitis

Apogee Therapeutics, Inc. Announces First Participants Dosed in Phase 1 Clinical Trial of APG333, its Novel Half-Life Extended TSLP Antibody for the Treatment of Respiratory and Broader I&I Conditions

Apogee Therapeutics Highlights Progress and Best-In-Class Potential of Novel Biologic Programs for I&I Diseases At 2024 Inaugural R&D Day Include

Apogee Therapeutics Earnings Preview: APG777's Potential In Atopic Dermatitis

Apogee Therapeutics, Inc. Announces Results Up to 9 Months from Phase 1 Trial of APG777, its Novel Half-Life Extended Anti-IL-13 Antibody for Treatment for Atopic Dermatitis and Other Inflammatory Diseases

Apogee Therapeutics, Inc. Appoints Jeff S. Hartness as Chief Commercial Officer

Apogee Therapeutics, Inc. Announces First Participants Dosed in Phase 1 Clinical Trial of APG990 its Novel Half-Life Extended OX40L Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases

Apogee Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $300 million.

Apogee Therapeutics: Infrequent Dosing Advantage In Biotech Play

Apogee Therapeutics, Inc. Appoints Lisa Bollinger to Its Board of Directors

Apogee Announces Dosing of First Patient in Phase 2 Atopic Dermatitis Trial of APG777, a Novel Subcutaneous Half-life Extended Anti-IL-13 Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases

Apogee Therapeutics, Inc., Annual General Meeting, Jun 05, 2024

Apogee Therapeutics Announces First Participants Dosed in Phase 1 Trial of APG808, its Novel Half-life Extended IL-4Ra Antibody for the Treatment of Chronic Obstructive Pulmonary Disease (COPD) and Other Inflammatory Diseases

Apogee Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $419.999966 million.

Apogee Therapeutics, Inc. has filed a Follow-on Equity Offering.

Apogee Therapeutics' Innovative Leap In Atopic Dermatitis Management

Apogee Therapeutics, Inc. Announces Positive Interim Results from Phase 1 Healthy Volunteer Trial for APG777, its Novel Half-Life Extended Anti-IL-13 Antibody for the Treatment for Atopic Dermatitis and Other Inflammatory Diseases

New minor risk - Share price stability

Apogee Therapeutics, Inc. and Paragon Therapeutics, Inc. Announce Two Abstracts Accepted for Presentation at the 2023 European Academy of Dermatology and Venereology (EADV) Congress

Apogee Therapeutics, Inc. Appoints Mark C. Mckenna as Chairman of Its Board of Directors

Apogee Therapeutics, Inc. has completed an IPO in the amount of $300.05 million.

Revenue & Expenses Breakdown

Earnings and Revenue History

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Return on Equity

Return on Assets

Return on Capital Employed

Discover strong past performing companies

Company Analysis and Financial Data Status

Data Sources

Analysis Model and Snowflake

Industry and Sector Metrics

Analyst Sources